• Supreme Court Decision Compels Brand-Name and Generic Drug Manufacturers Alike to Rethink Hatch-Waxman Litigation Strategies
  • June 21, 2013
  • Law Firm: Cadwalader Wickersham Taft LLP - New York Office
  • On June 17, 2013, in a decision long-awaited by antitrust and intellectual property practitioners, the U.S. Supreme Court ruled that so-called pharmaceutical "reverse payment" agreements are not immune from antitrust scrutiny but must be analyzed under the rule of reason.